Krystal Biotech Inc
Research Krystal Biotech Inc (KRYS) on Bullrun: valuation model: 15.8% overvalued, market cap USD 11.15B, P/E 50.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKRYS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal15.8% overvalued
- Market capUSD 11.15B
- P/E50.5
- Financial periodFY2025
- RevenueUSD 389.13M
- Revenue growth33.9%
- Net incomeUSD 204.83M
- Free cash flowUSD 188.91M
Valuation Snapshot
Bullrun's latest valuation model marks Krystal Biotech Inc as 15.8% overvalued; latest market cap is USD 11.15B; P/E is 50.5.
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis;
Frequently asked questions
Is Krystal Biotech Inc overvalued or undervalued?
Bullrun's valuation model currently marks Krystal Biotech Inc as 15.8% overvalued.
What is Krystal Biotech Inc's market cap?
Krystal Biotech Inc's market capitalization is USD 11.15B.
What is Krystal Biotech Inc's P/E ratio?
Krystal Biotech Inc's price-to-earnings (P/E) ratio is 50.5.
What does Krystal Biotech Inc do?
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.